Drug Trial Radar · NCT07010159
Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
325
Planned (sponsor's estimate)
Start
Jul 25, 2025
Primary completion
Dec 31, 2027
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Kiniksa Pharmaceuticals International, plcIndustry
- Sponsor type
- Industry
- Collaborators
- Kiniksa Pharmaceuticals, GmbH
- First posted
- Jun 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.
Conditions
- Pericarditis
- Pericarditis Acute
- Recurrent Pericarditis
Interventions
KPL-387Drug
administered by subcutaneous injection
PlaceboDrug
administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2: Time to Treatment Response by Week 24Time frame: From Baseline up to Week 24
- Phase 3: Time to Pericarditis RecurrenceTime frame: From Baseline in the RW Period
- Long-Term Extension: Annualized rate of Pericarditis RecurrenceTime frame: Up to 24 Months
Locations
67 sites in 10 countries. Site status is shown where the registry gives one.
Investigational Site 018
Gilbert, Arizona · Recruiting
Investigational Site 053
Phoenix, Arizona · Recruiting
Investigational Site 064
La Jolla, California · Recruiting
Investigational Site 030
Los Angeles, California · Recruiting
Investigational Site 008
San Francisco, California · Recruiting
Investigational Site 044
Santa Monica, California · Recruiting
Investigational Site 058
Ventura, California · Recruiting
Investigational Site 016
Westminster, Colorado · Recruiting
Investigational Site 061
Washington D.C., District of Columbia · Recruiting
Investigational Site 067
Kissimmee, Florida · Recruiting
Investigational Site 001
Columbus, Georgia · Withdrawn
Investigational Site 004
Chicago, Illinois · Recruiting
Investigational Site 014
Indianapolis, Indiana · Recruiting
Investigational Site 002
Overland Park, Kansas · Withdrawn
Investigational Site 043
Baltimore, Maryland · Recruiting
Investigational Site 054
Boston, Massachusetts · Recruiting
Investigational Site 055
Minneapolis, Minnesota · Recruiting
Investigational Site 012
Rochester, Minnesota · Recruiting
Investigational Site 050
Kansas City, Missouri · Recruiting
Investigational Site 046
Kansas City, Missouri · Recruiting
Investigational Site 062
St Louis, Missouri · Recruiting
Investigational Site 015
New York, New York · Recruiting
Investigational Site 022
New York, New York · Recruiting
Investigational Site 009
Cincinnati, Ohio · Recruiting
Investigational Site 003
Cleveland, Ohio · Recruiting
Investigational Site 005
Austin, Texas · Recruiting
Investigational Site 066
Houston, Texas · Recruiting
Investigational Site 013
Houston, Texas · Recruiting
Investigational Site 042
Burlington, Vermont · Recruiting
Investigational Site 006
Charlottesville, Virginia · Recruiting
Investigational Site 023
Norfolk, Virginia · Recruiting
Investigational Site 045
Richmond, Virginia · Recruiting
Investigational Site 065
Seattle, Washington · Recruiting
Investigational Site 027
Ottawa, Ontario, Canada · Recruiting
Investigational Site 028
Montpellier, France · Recruiting
Investigational Site 021
Paris, France · Recruiting
Investigational Site 036
Pessac, France · Recruiting
Investigational Site 019
Poitiers, France · Recruiting
Investigational Site 037
Toulouse, France · Recruiting
Investigational Site 038
Toulouse, France · Recruiting
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.